Influenza A and influenza B both cause seasonal flu, produce nearly identical symptoms, and circulate during the same winter months. The real differences between them are biological: how they mutate, what species they infect, and whether they can trigger pandemics. These distinctions matter because they shape how dangerous each type is on a population level and how vaccines are designed to fight them.
Host Range and Pandemic Risk
The single biggest difference between influenza A and B is which species they can infect. Influenza A circulates in wild birds, pigs, horses, dogs, and other animals in addition to humans. More than 130 subtype combinations of influenza A have been identified in nature, primarily in wild birds, and the actual number of possible combinations is likely much higher. This enormous animal reservoir gives influenza A the raw material to produce entirely new virus strains that human immune systems have never encountered.
Influenza B, by contrast, primarily infects humans. It doesn’t maintain the same broad animal reservoir, which limits its ability to generate radically new strains. This is why every flu pandemic in recorded history has been caused by influenza A, never influenza B. The 1918, 1957, 1968, and 2009 pandemics all originated from influenza A viruses that jumped from animal populations into humans.
How Each Type Mutates
Both influenza A and B undergo a process called antigenic drift, where small mutations accumulate as the virus copies itself. These gradual changes alter the virus’s surface proteins just enough that your immune system may not fully recognize it from one season to the next. This is the main reason you need a new flu shot every year.
Influenza A, however, has an additional trick: antigenic shift. This is an abrupt, major change where the virus acquires entirely new surface proteins, often by mixing genetic material with an animal flu virus. The result is a strain so different from previous human viruses that most people have little or no immunity to it. When this happens, a pandemic can follow. Influenza B does not undergo antigenic shift because it lacks the broad animal host range needed to swap genetic material across species in this way.
Symptoms Are Essentially the Same
If you’re lying in bed with the flu, you won’t be able to tell whether you have type A or type B based on how you feel. Both cause fever, body aches, cough, sore throat, fatigue, and sometimes vomiting or diarrhea. The onset is typically sudden, and the course of illness lasts about the same amount of time regardless of type.
One notable clinical difference involves a rare neurologic complication called Reye syndrome, which is more commonly associated with influenza B than influenza A. Reye syndrome has become extremely uncommon since doctors stopped recommending aspirin for children with flu or chickenpox in the early 1980s, but it’s the reason children and teenagers with flu symptoms should avoid aspirin.
Severity and Who Gets Hit Hardest
There’s a widespread assumption that influenza B is the “milder” type, but the data don’t support that. Both types cause similar rates of hospitalization, ICU admission, and serious complications. One Canadian study found that mortality among hospitalized patients was actually higher with influenza B (1.1%) than influenza A (0.4%).
The two types do tend to affect slightly different age groups. Influenza A skews younger in children, with an average age of about 4 years in pediatric studies, while influenza B tends to hit older children harder, with an average age closer to 5.6 years. Children aged 5 to 14 are more than twice as likely to be infected with influenza B compared to younger kids. Both types can cause serious complications in children, including neurologic problems (seen in 8 to 11 percent of hospitalized children), bacterial pneumonia, and ear infections.
Vaccine Coverage for Both Types
Seasonal flu vaccines are designed to protect against both influenza A and influenza B. For the 2024-2025 season in the United States, all flu vaccines are trivalent, meaning they contain three components: two influenza A strains and one influenza B strain. The A components target the H1N1 and H3N2 subtypes, which are the two influenza A subtypes currently circulating in humans. The B component targets the Victoria lineage, which is the influenza B lineage still in active circulation.
Influenza B historically split into two lineages, Victoria and Yamagata, but the Yamagata lineage has not been detected in circulation for several years. This is why vaccines shifted from four components (quadrivalent) to three (trivalent) starting with the 2024-2025 season.
How Testing Works
Rapid flu tests can distinguish between influenza A and B, but they’re far from perfect. These tests have a sensitivity of roughly 50 to 70 percent, meaning they miss a significant number of true infections. If you test negative on a rapid test during peak flu season, you could still have the flu. The FDA now requires newer rapid tests to achieve at least 80 percent sensitivity compared to more advanced laboratory methods.
The specificity of rapid tests is much better, around 95 to 99 percent. A positive result is generally reliable. More precise molecular tests (RT-PCR) are available and can confirm the diagnosis when rapid results are negative but flu is still suspected. These molecular tests also identify the specific subtype of influenza A, which matters for public health surveillance even if it doesn’t change your treatment.
What This Means in Practice
For any individual person sick with the flu, the type rarely changes what happens next. The same antiviral treatments work against both influenza A and B, and the same supportive care (rest, fluids, fever management) applies. The distinction between A and B matters most at the population level: influenza A’s ability to undergo dramatic genetic shifts means it poses a unique threat as the source of future pandemics, while influenza B evolves more slowly and predictably. Both types are capable of causing severe illness and death in any given flu season, and the annual vaccine is formulated to cover both.